Cystic fibrosis year in review 2019: Section 1 CFTR modulators
- 24 August 2020
- journal article
- review article
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (12) , 3236-3242
Abstract
During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance. To adequately address the large body of CF research published during 2019, the CF year in review will be divided into three sections. This report is the first section, focusing specifically on new research related to cystic fibrosis transmembrane conductance regulator modulator therapy. Additional sections will concentrate on pulmonary and infections research and the multisystem effects of CF. It is an exciting time to be providing care for patients and their families with CF with all the exciting new discoveries that will be shared in these reviews.Keywords
This publication has 35 references indexed in Scilit:
- Predictive factors for lumacaftor/ivacaftor clinical responseJournal of Cystic Fibrosis, 2019
- CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic FibrosisAnnals of the American Thoracic Society, 2019
- IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutationJournal of Cystic Fibrosis, 2019
- Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatmentJournal of Cystic Fibrosis, 2019
- Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1Journal of Cystic Fibrosis, 2019
- Incretin hormones: Their role in health and diseaseDiabetes, Obesity and Metabolism, 2018
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delNew England Journal of Medicine, 2017
- The suppression of premature termination codons and the repair of splicing mutations in CFTRCurrent Opinion in Pharmacology, 2017
- Functional Properties of Mixed Cystic Fibrosis and Normal Bronchial Epithelial Cell CulturesAmerican Journal of Respiratory Cell and Molecular Biology, 2009